Key result
Patients with HFmrEF represented an intermediate phenotype with a 42.4% readmission rate, but resembled HFrEF with a higher incidence of ischemic heart disease.
Why the study?
What are the clinical characteristics, precipitants, and outcomes of patients with HFmrEF compared to those with HFpEF and HFrEF?
Cohort (n=5,236)
What are the clinical characteristics, precipitants, and outcomes of patients with HFmrEF compared to those with HFpEF and HFrEF?
HFmrEF represents an intermediate clinical phenotype between HFrEF and HFpEF, except for a higher incidence of ischemic heart disease resembling HFrEF, with similar mortality across all three groups.
Supports ischemic scrutiny in HFmrEF akin to HFrEF; leaves open whether phenotype-tailored strategies improve outcomes.
AIMS: The aim of this study was to compare precipitants, presenting symptoms and outcomes of patients with heart failure and mid-range ejection fraction (HFmrEF), heart failure and preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in an Australian cohort. METHODS: We divided 5236 patients in the Management of Cardiac Failure program in Northern Sydney Australia, into HFmrEF (n = 780, 14.9%), HFpEF (n = 1956, 37.4%) and HFrEF (n = 2500, 47.8%), using a cutoff left ventricular ejection fraction of 40-49, at least 50 and less than 40%, respectively. RESULTS: For most characteristics, the HFmrEF patients were intermediate. Hypertension among the HFrEF, HFmrEF and HFpEF groups was present in 50.6, 61.7 and 68.9%, respectively; age more than 85 years was present in 35.1, 37.6 and 42.2%; atrial fibrillation in 35.3, 44.2 and 49.9%; and elevated serum creatinine (>100 μmol/l) in 59.2, 55.6 and 51.0%. For ischemic heart disease and ischemia as a precipitant of admission, HFmrEF patients were similar to the HFrEF group, and more common than in HFpEF. Mortality rates were not significantly different between the three groups. Readmission rates were highest for HFpEF (40.2%), followed by HFmrEF (42.4%) and HFrEF (45.4%), largely due to differences in nonheart failure readmission. CONCLUSION: Clinically, HFmrEF represents an intermediate phenotype, with the exception of resembling HFrEF with a higher incidence of ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) conducted a cohort in Heart failure (n=5,236). Heart failure with mid-range ejection fraction (HFmrEF) vs. HFpEF and HFrEF was evaluated on Readmission rates. Patients with HFmrEF represented an intermediate phenotype with a 42.4% readmission rate, but resembled HFrEF with a higher incidence of ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: